The device has been tested on Israeli soldiers.
Prism is a two-part device that focuses on helping patients control the activity of their amygdala, the area of the brain primarily responsible for the control of emotion and memory.
“When a patient is successful in lowering the activity of the amygdala, or the amygdala-related signal, then they get positive feedback from the device,” Prof. Talma Hendler, professor of neuroscience and psychiatry at Tel Aviv University, director of the Sagol Brain Institute at the Tel Aviv Sourasky Medical Center and developer of the technology, told ThePrism, she argued, teaches patients the mental strategy that moves their emotional system to a calmer state.
She now expects Prism to be commercially available for doctors to prescribe starting in 2024. However, it will not be made available everywhere focusing instead primarily on outpatient and private clinics where staff can be trained in its use and administration.“When the patient is successful in regulating their limbic system, then the room relaxes, as well. Figures start to sit down and the noises are lowered. So it is kind of resonant with the patient’s brain. This is the positive feedback.
“We found that the soldiers who had more amygdala activity prior to going into action developed more PTSD symptoms. This was the initial hint that amygdala hyper-activation is a marker for possibility developing psychopathology following trauma,” Hendler
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
The Tools That Help Employees Make the Right Health Care Choices - SPONSOR CONTENT FROM EMBOLD HEALTHSponsored: The Tools That Help Employees Make the Right Health Care Choices from Embold Health
Baca lebih lajut »
‘Yellowjackets’ Executive Producers Explain Themes of Trauma and PTSD Explored in Season 2“Each survivor must determine if the darkness is coming for them or from them,” reads Showtime’s official description for Season 2 of “Yellowjackets” and the writers t…
Baca lebih lajut »
FDA Panel Backs Accelerated Approval for Biogen's ALS DrugA panel of advisers to the drug regulator voted that data on Biogen's experimental treatment for ALS, shows that the drug could work, potentially paving the way for an accelerated approval.
Baca lebih lajut »
Analysis-In US abortion pill case, FDA could soften blow of court-ordered restrictionsA conservative federal judge in Texas could soon order the U.S. Food and Drug Administration to reconsider its 22-year-old approval for a pill used in the most common form of abortion in the United States, or order the approval revoked outright. Of the various potential rulings possible in the case involving the abortion pill mifepristone, either of those outcomes would be unprecedented judicial intervention in the agency's regulatory process. The FDA declined to comment on the litigation or its next steps.
Baca lebih lajut »
I'm helping doctors take FDA to court over dangerous drugs that kill womenLawsuit asks the court to hold the Food and Drug Administration accountable for recklessly approving chemical abortion drugs that harm women and girls.
Baca lebih lajut »
US FDA approves Pharming's immune disorder drugThe U.S. Food and Drug Administration (FDA) on Friday approved Pharming Group's drug to treat a rare genetic disorder that leads to a weakened immune system, the Dutch company said.
Baca lebih lajut »